NBHL Drug Screening Key Characteristics
Started research programs in 2007
 
 

Research center :

A1-#551 12-18, Kamiaoki 3 Kawaguchi City, Saitama3330844, Japan

 
 

Director :

Kiyoshi TAKAYAMA,PhD  
 

Scientific Advisor :

Peter Libby,MD
(Harvard Medical School BWH / vascular diseases)
Hiroshi KIDA, PhD
(Hokkaido Univ Research Center for Zoonosis Control, Director)

  
 

Collaborators :

Tomoyuki NAKAMURA,MD,PhD
(Kansai Medical Univ., Professor vascular diseases)
Toshitaka MAENO,MD,PhD
(Gunmma Univ., Assistant Professor, COPD)
Jun-ich SUZUKI,MD,PhD
(Tokyo Univ., Associate Professor, vascular diseases)
Kazuki HONDA,PhD
(ex Tokyo Medical and Dental School,Professor,Sleeping disorder)
Steven D Shapiro,MD
(Univ. of Pittsburgh School of Medicine, Professor,COPD)

  


Research platform
  From target discovery to Lead optimization for preclinical candidate.  
 
1)screening small compounds in vitro (in vivo)
2)screening functional Monoclonal antibodies
  


Target diseases
 
1)Vascular diseases
(atherosclerosis, aneurysm, stroke and vascular disorders in diabetes mellitus.)
2)COPD, other acute and chronic inflammatory diseases.
3)Sleeping disorder.
  


Contact information
  E-mail:  
  Address: #110 Hokudai Business Spring, Kita 21-jo Nishi 11-chome, Kita Ward Sapporo City, Hokkaido 001-0021, Japan  
  to form mail page